Boehringer aims for new Pradaxa use in hip surgery; Merck asks judge to toss Integrilin marketing claims;

@FiercePharma: What's Next For The Thousands Of Angry Men Suing Over Testosterone? Forbes article | Follow @FiercePharma

@CarlyHFierce: ICYMI: Pfizer shutters vaccine sales business in China after Prevenar setback. Story | Follow @CarlyHFierce

> The FDA accepted Boehringer Ingelheim's application for broader use of its anticoagulant Pradaxa, to prevent deep vein thrombosis and pulmonary embolism after hip replacement surgery. Release

> Merck & Co. ($MRK) asked a California judge to dismiss whistleblower claims in a lawsuit over its marketing of the drug Integrilin, after similar claims against its partner Millennium were tossed out. Report (sub. req.)

> Teva Pharmaceutical Industries ($TEVA) struck a $24 million deal to escape a Nexium pay-for-delay suit. Report (sub. req.)

> Juno Therapeutics ($JUNO) settled a patent fight with Novartis ($NVS) and the University of Pennsylvania, over a deal that includes a $12.25 million up-front payment from the drugmaker and future milestones and royalties on any related drugs eventually approved. Release

> As their pharma exports slump, Australian drugmakers are seeking government incentives to boost their competitiveness in other countries. Report

> An antibiotic-resistant strain of the gastrointestinal bacteria shigella is spreading in the U.S. Report (sub. req.)

Medical Device News

@FierceMedDev: Check out the top med tech companies of 2014. Feature | Follow @FierceMedDev

@StacyALawrence: ICYMI: FDA to investigate Bayer's birth control device after allegations of trial fraud. Story | Follow @StacyALawrence

@VarunSaxena2: ICYMI: Medtronic tries again in renal denervation after previous trial failure. Article | Follow @VarunSaxena2

@EmilyWFierce: Medtronic grabs artificial pancreas tech from Israeli devicemaker. Report | Follow @EmilyWFierce

> U.S. health insurers consider new curbs on morcellators amid regulatory pushback. Article

> Medtronic pays feds $4.4 million over DOJ allegations that it falsely labeled devices as made in the USA. Story

Biotech News

@FierceBiotech: ICYMI: GlaxoSmithKline to create new vaccines hub, uprooting groups in Cambridge, Philly. Report | Follow @FierceBiotech

@JohnCFierce: You rarely see a real battle to the death in biotech over patents. Usually, it all gets down to a reasonable set of numbers. | Follow @JohnCFierce

> MorphoSys: That Celgene-abandoned cancer drug isn't dead yet. Report

> Juno and Novartis settle CAR-T patent fight with little fanfare. More

> Bristol-Myers bets big on gene therapy with a $1B uniQure deal. Article

Animal Health News

> TVAX pours $2M funding round into canine osteosarcoma drug. More

> UN launches global campaign to wipe out ruinous sheep and goat virus. Article

> Under pressure, Zoetis pulls arsenic-based poultry drug from market. News

> Homeland Security names program manager for new NBAF facility in Kansas. Story

> Texas Tech scientists discover that antibiotic-resistant bugs from cattle lots are airborne. Report

Biotech IT News

> Celgene, Genentech back clinical trial enrollment challenge. News

> Potency prediction software helps Schrödinger land $120M Sanofi deal. Report

> Genentech begins search for bioinformatics chief after Gentleman leaves for 23andMe. Story

> 23andMe-style sequencing project taps Facebook in pursuit of 20,000 participants. Article

> Genome Canada makes $24M pivot to bolster bioinformatics capabilities. More

And Finally... Statin drugs can have some sexual side effects, good and bad, experts point out. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.